...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: New trial
3
May 25, 2021 10:36PM
3
May 26, 2021 09:35AM
3
May 26, 2021 01:25PM
2
May 26, 2021 02:56PM
4
May 27, 2021 04:13PM

It did lessen the value of RVX by the value of the IP moved to Zenith. At the time, RVX value that at and maybe some cash, royaltiy shares,  etc. at 9.1% of pre-spinout RVX. That is what we paid for the Zenith shares.

3
May 28, 2021 11:12PM
3
May 29, 2021 10:08AM
2
May 29, 2021 10:12AM
Share
New Message
Please login to post a reply